There are more than 70 distinct sarcomas, and this diversity complicates the development of
precision-based therapeutics for these cancers. Prospective comprehensive genomic …

The genetic, biologic, and clinical heterogeneity of sarcomas poses a challenge for the
identification of therapeutic targets, clinical research, and advancing patient care. Because …

Importance Patients with advanced soft-tissue sarcomas (STS) have a median overall
survival of less than 18 months. Identification of molecular abnormalities for which targeted …

Increasingly, human mesenchymal malignancies are being classified by the abnormalities
that drive their pathogenesis. Although many of these aberrations are highly prevalent within …

Soft tissue sarcomas (STS) are rare and heterogeneous tumours comprising over 80
different histological subtypes. Treatment options remain limited in advanced STS with high …

Sarcomas are a broad family of mesenchymal malignancies exhibiting remarkable histologic
diversity. We describe the multi-platform molecular landscape of 206 adult soft tissue …

Sarcomas are a broad family of mesenchymal malignancies exhibiting remarkable histologic
diversity. We describe the multi-platform molecular landscape of 206 adult soft tissue …

Soft-tissue sarcomas, which result in approximately 10,700 diagnoses and 3,800 deaths per
year in the United States, show remarkable histologic diversity, with more than 50 …

Background There are currently no United States Food and Drug Administration approved
molecularly matched therapies for sarcomas except gastrointestinal stromal tumors …

Sarcomas are a heterogeneous group of malignancies that arise from cells of a
mesenchymal origin. Surgery forms the mainstay of the treatment of most patients with …